Anti-inflammatory drug shows early promise in ACS
MedWire News: The investigational anti-inflammatory drug VIA-2291 reduces leukotriene (LT) production and prevents the formation of new coronary plaques in patients with recent acute coronary syndrome (ACS), a small, randomized trial shows.
VIA-2291 inhibits LT production by 5-lipoxygenase, which has been linked to atherosclerotic plaque instability and cardiovascular events.
In the double-blind trial, 191 patients were randomly assigned 3 weeks after an ACS to receive 25, 50, or 100 mg VIA-2291 or placebo daily for 12 weeks.
Results showed that whole-blood LBT4 levels reduced significantly with VAI-2291 treatment in a dose-dependent fashion, with 80% inhibition in over 90% of patients receiving the 100-mg dose.
Among 60 patients who completed a further 12 weeks of treatment, 64-slice coronary computed tomography showed that new plaques developed in five (27.8%) of 18 placebo-treated patients compared with two (4.8%) of 42 VIA-2291-treated patients (p=0.01).
Furthermore, noncalcified plaque volume was reduced in the VIA-2291 group compared with the placebo group among 34 of the 60 patients in whom the endpoint could be analyzed (p<0.01).
“Up to now, standard treatments for patients with ACS have not specifically reduced inflammation, an important component of atherosclerosis,” commented lead investigator Jean-Claude Tardif (Montreal Heart Institute, Quebec, Canada).
“The findings we’re publishing show that VIA-2291 may finally offer the solution we need to target and reduce inflammation,” added Tardif who also said the findings support evaluation of VIA-2291 in larger trials.
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
By Caroline Price